We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination.
- Authors
Speletas, Matthaios; Voulgaridi, Ioanna; Bogogiannidou, Zacharoula; Sarrou, Styliani; Kyritsi, Maria A.; Theodoridou, Aikaterini; Dadouli, Katerina; Matziri, Alexia; Vontas, Alexandros; Pappa, Dimitra; Konstantinou, Adamos-Konstantinos; Tsigalou, Christina; Kalala, Fani; Mouchtouri, Varvara A.; Hadjichristodoulou, Christos
- Abstract
During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (p = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease.
- Subjects
BOOSTER vaccines; SARS-CoV-2; COVID-19 vaccines; ADENOVIRUS diseases; IMMUNOGLOBULIN G; IMMUNOGLOBULIN A
- Publication
Vaccines, 2024, Vol 12, Issue 1, p12
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines12010012